Opportunity

Support the rapid and reliable execution of clinical data studies to bring medicines to the market faster.

Results

20X

increased performance

Products & Solutions

UCB

Belgian pharmaceutical company increases data availability and speeds analysis for clinical studies.

As a developer of high-quality medicines for people with afflictions such as epilepsy, rheumatoid arthritis, and Parkinson’s disease, UCB is constantly racing against the clock to combine speed and quality. Based on clinical studies in which a new medication is tested in an experimental setting, the scientists and analysts of UCB collect and analyze the necessary data for the further development of medicines. The analytical results from these studies serve as the foundation for the approval of new medicines by the governing authorities and for scientific publication.

The strong data growth forced us to look for a new storage solution that would enable us to process larger data volumes, generating analysis and results much faster. In clinical studies, enormous amounts of data are analyzed at high speed.

"We decided to choose NetApp because we already work with a NetApp storage environment and it gave us the opportunity to enhance our roadmap,” says De Prins.

As far as support for the output of clinical studies was concerned, the test projects convinced UCB to switch from traditional storage to flash technology and to choose the NetApp EF540 flash array as the optimal solution.

"The NetApp EF540 flash array fulfills all these demands, not only by offering maximum reliability, but speed as well. Depending on the analyses and queries that have to be executed, we have realized a 20-times increase in speed with this flash technology. This is really unprecedented and crucial to the playing field we operate in," says De Prins.

About this Customer

UCB

UCB has its headquarters in Brussels and is a globally operating biopharmaceutical company with more than 9,000 employees. The company is active in 40 countries and has an annual revenue of €3.4 billion, with numerous strategic partnerships in the pharmaceutical sector. UCB focuses specifically on the development of innovative medicines and groundbreaking solutions for people who suffer from serious disorders of the central nervous system or the immune system.

More Customer Stories

Global Eagle Entertainment

Redesigning the Video Production Workflow

Learn More

Inova Translational Medicine Institute

Accelerates Research Results with Private Cloud

Learn More

University of California, Los Angeles (UCLA)

Accelerating Research Time to Market

Learn More

Data Solutions for the Modern Business

Contact Sales